Related Experiment Videos
[Skin tests and chymopapain-specific immunoglobulins E after chemonucleolysis]
This study looked at how often people become allergic to chymopapain after a medical procedure called chemonucleolysis. Researchers tested three groups: patients before and after the procedure, and a group of people with known allergies. They found that only 1.33% of patients had a skin reaction to chymopapain before the procedure, but this rose to 26.2% after the procedure. Blood tests showed a similar increase in allergy-related proteins. The study suggests that the procedure itself can cause new allergies. Skin testing was found to be a reliable and cost-effective way to detect this risk. The results support using skin tests to identify patients at risk before surgery.
Area of Science:
- Immunology diagnostic techniques
- Allergy and hypersensitivity testing
- Orthopedic surgical outcomes
Background:
Prior research has established that skin testing is a common method for detecting IgE-mediated hypersensitivity. However, the frequency of sensitization to chymopapain in non-atopic populations remained unclear. It was already known that atopic individuals are more prone to allergic reactions. No prior work had resolved whether chemonucleolysis itself could induce sensitization. This gap motivated the need to compare sensitization rates across groups. The study aimed to clarify whether chemonucleolysis contributes to new sensitization. No prior work had tested concordance between skin tests and IgE levels for chymopapain. The literature lacked data on the reliability of skin testing in this context.
Purpose Of The Study:
The study aimed to assess sensitization to chymopapain in patients undergoing chemonucleolysis. Researchers wanted to compare sensitization rates between patients before and after the procedure. They also sought to evaluate differences between atopic and non-atopic groups. The goal was to determine whether chemonucleolysis itself could cause sensitization. The study aimed to assess the reliability of skin testing for chymopapain allergy. Researchers also wanted to test the concordance between skin tests and IgE levels. The primary objective was to evaluate the diagnostic value of prick tests. The study aimed to inform clinical practice regarding preoperative allergy screening.
Main Methods:
The study divided participants into three groups: patients awaiting chemonucleolysis, patients post-procedure, and atopic patients with known allergies. Skin prick tests were performed using a 10 mg/ml chymopapain solution. Blood samples were collected to measure chymopapain-specific IgE levels. The first group included 75 patients pre-procedure. The second group included 42 of these patients two to three weeks post-treatment. The third group included 60 atopic patients with known airborne allergen sensitivities. Researchers compared sensitization rates across the groups. Statistical analysis was used to assess significance. Concordance between skin test results and IgE levels was calculated.
Main Results:
One of 75 patients in group I had a positive skin test (1.33%). One of 60 patients in group III had a positive test (1.7%). Eleven of 42 patients in group II had a positive result (26.2%). Chymopapain-specific IgE was found in 1 of 75 patients pre-procedure (1.33%). Fourteen of 45 patients post-procedure had detectable IgE (31%). The difference between pre- and post-procedure IgE levels was significant (P < 0.001). Concordance between skin tests and IgE levels reached 74%. These findings suggest chemonucleolysis increases sensitization risk.
Conclusions:
The authors propose that chemonucleolysis has a highly significant sensitizing effect (P < 0.001). They suggest that sensitization to chymopapain is not more common in atopic patients. The study shows that skin testing can detect sensitization after chemonucleolysis. The authors state that skin tests with a 10 mg/ml solution are reliable for risk detection. They propose that skin testing is a simple and cost-effective method. The study supports prior literature on chymopapain allergy. The authors suggest that preoperative testing could reduce allergic reactions. They conclude that skin testing remains a valid diagnostic tool.
Frequently Asked Questions
The study suggests that chemonucleolysis increases the risk of chymopapain allergy. Sensitization rose from 1.33% to 31% post-procedure (P < 0.001).
Sensitization was measured using skin prick tests and chymopapain-specific IgE levels in blood.
The authors propose that this concentration is reliable for detecting sensitization based on their results.
The 74% concordance suggests skin testing is a valid method for detecting chymopapain allergy.
Fourteen out of 45 patients had detectable chymopapain-specific IgE levels post-procedure.
The authors suggest skin testing with a 10 mg/ml solution is a simple, reliable method for allergy detection.